These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 35056723

  • 21. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R, Fatima I, Chandra V, Blesson CS, Kharkwal G, Hussain MK, Hajela K, Roy BG, Dwivedi A.
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [Abstract] [Full Text] [Related]

  • 22. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, Smid M, Zhang Y, van de Water B.
    Breast Cancer Res; 2019 Jul 01; 21(1):77. PubMed ID: 31262335
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Antineoplastic effects of α-santalol on estrogen receptor-positive and estrogen receptor-negative breast cancer cells through cell cycle arrest at G2/M phase and induction of apoptosis.
    Santha S, Bommareddy A, Rule B, Guillermo R, Kaushik RS, Young A, Dwivedi C.
    PLoS One; 2013 Jul 01; 8(2):e56982. PubMed ID: 23451128
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells.
    Wang HC, Hu HH, Chang FR, Tsai JY, Kuo CY, Wu YC, Wu CC.
    Phytomedicine; 2019 Feb 01; 53():213-222. PubMed ID: 30668401
    [Abstract] [Full Text] [Related]

  • 27. Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells.
    Ahmed SA, Mendonca P, Messeha SS, Soliman KFA.
    Molecules; 2023 Sep 09; 28(18):. PubMed ID: 37764312
    [Abstract] [Full Text] [Related]

  • 28. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D, Siddique AB, Qusa M, Cyprian FS, El Sayed K, Alali F, Al Moustafa AE, Khalil A.
    Eur J Med Chem; 2020 Feb 01; 187():111954. PubMed ID: 31838326
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells.
    Fang Y, Zhang Q, Wang X, Yang X, Wang X, Huang Z, Jiao Y, Wang J.
    Int J Oncol; 2016 Mar 01; 48(3):1016-28. PubMed ID: 26783066
    [Abstract] [Full Text] [Related]

  • 31. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
    Chen J, Wang W, Wang H, Liu X, Guo X.
    Drug Discov Ther; 2014 Feb 01; 8(1):33-41. PubMed ID: 24647156
    [Abstract] [Full Text] [Related]

  • 32. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
    Kuo YH, Chiang EI, Chao CY, Rodriguez RL, Chou PY, Tsai SY, Pai MH, Tang FY.
    Mol Cancer Ther; 2017 Mar 01; 16(3):480-493. PubMed ID: 27956520
    [Abstract] [Full Text] [Related]

  • 33. The molecular mechanism of the anticancer effect of Artonin E in MDA-MB 231 triple negative breast cancer cells.
    Etti IC, Abdullah R, Kadir A, Hashim NM, Yeap SK, Imam MU, Ramli F, Malami I, Lam KL, Etti U, Waziri P, Rahman M.
    PLoS One; 2017 Mar 01; 12(8):e0182357. PubMed ID: 28771532
    [Abstract] [Full Text] [Related]

  • 34. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
    Liang S, Peng X, Li X, Yang P, Xie L, Li Y, Du C, Zhang G.
    Oncotarget; 2015 Jan 20; 6(2):1020-30. PubMed ID: 25544759
    [Abstract] [Full Text] [Related]

  • 35. Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells.
    Messeha SS, Noel S, Zarmouh NO, Womble T, Latinwo LM, Soliman KFA.
    Cancer Genomics Proteomics; 2023 Jan 20; 20(4):323-342. PubMed ID: 37400144
    [Abstract] [Full Text] [Related]

  • 36. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y, Hu S, Chen Y, Zhang X, Gao H, Tian J, Chen J.
    Phytomedicine; 2023 Sep 20; 118():154924. PubMed ID: 37393829
    [Abstract] [Full Text] [Related]

  • 37. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP, Yang YX, Liu QL, Pan ST, He ZX, Zhang X, Yang T, Chen XW, Wang D, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Sep 20; 9():1627-52. PubMed ID: 25834401
    [Abstract] [Full Text] [Related]

  • 38. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
    Wu J, Ding Y, Chen CH, Zhou Z, Ding C, Chen H, Zhou J, Chen C.
    Cancer Lett; 2016 Oct 01; 380(2):393-402. PubMed ID: 27387452
    [Abstract] [Full Text] [Related]

  • 39. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
    Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC.
    Oncotarget; 2015 Oct 20; 6(32):32856-67. PubMed ID: 26439989
    [Abstract] [Full Text] [Related]

  • 40. ERK-modulated intrinsic signaling and G(2)/M phase arrest contribute to the induction of apoptotic death by allyl isothiocyanate in MDA-MB-468 human breast adenocarcinoma cells.
    Tsai SC, Huang WW, Huang WC, Lu CC, Chiang JH, Peng SF, Chung JG, Lin YH, Hsu YM, Amagaya S, Yang JS.
    Int J Oncol; 2012 Dec 20; 41(6):2065-72. PubMed ID: 23008020
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.